Home   >  
Angiogenesis/Protein Tyrosine Kinase

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Acrizanib Chemical Structure
BCP36110 Acrizanib 1229453-99-9
Acrizanib is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-KDR.
SAR131675 Chemical Structure
BCP35024 SAR131675 1433953-83-3
SAR131675 is a potent and selective VEGFR3 inhibitor with an IC50 of 23 nM.
(Z)-Guggulsterone Chemical Structure
BCP07472 (Z)-Guggulsterone 39025-23-5
Z-guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. Z-guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis.
5Z-7-Oxozeaenol Chemical Structure
BCP34467 5Z-7-Oxozeaenol 253863-19-3
5Z-7-Oxozeaenol is a covalent inhibitor that acts against the several protein kinases (e.g. ERK2 and TAK1) that possess a free cysteine at the gatekeeper-2 position.
Donafenib Chemical Structure
BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
TAS-115 mesylate Chemical Structure
BCP34015 TAS-115 mesylate 1688673-09-7
TAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
TAS-115 Chemical Structure
BCP34014 TAS-115 1190836-34-0
TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
SU 5205 Chemical Structure
BCP25520 SU 5205 3476-86-6
SU 5205 is a VEGFR2 inhibitor.
Vandetanib trifluoroacetate Chemical Structure
BCP33121 Vandetanib trifluoroacetate 338992-53-3
Vandetanib trifluoroacetate is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
PTC299 Chemical Structure
BCP32869 PTC299 1256565-36-2
PTC299 is a potent, orally bioavailable VEGFA inhibitor, targets dihydroorotate dehydrogenase (DHODH), resulting in cell growth inhibition and differentiation in leukemias, including acute myeloid leukemia, linking DHODH regulation and stress-induced VEGFA and angiogenesis.
123下一頁末頁共 129 條記錄 1 / 13 頁 
福建36选7奖金 2月10日雷霆vs尼克斯 海南4+1开奖结果昨天 二分彩开奖结果 晓游棋牌游戏大厅手机下载 青海快三开奖时间 辽宁福彩快乐12走势图 福彩3d综合走势图 掌上福建麻将安卓 欢乐广西南宁麻将 捕鱼来了功率 大乐透下期预测汇总 江苏十一选五推荐任三 管家婆资料大全管家婆2019 pc蛋蛋辅助器 江苏体彩七位数走势图综合版 广西麻将吧